2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1994

Erosion Depth Predicts Erosion Progression in Patients with Early RA: A Longitudinal Analysis Using HR-pQCT
Abstract Number: 589

Erosions at the Sacroiliac Joints and Fatty Lesions at the Spine Are the Most Discriminant Lesions for Recent Onset Axial Spondyloarthritis Recognition
Abstract Number: 1233

Establishing and Maintaining a Volunteer Charity Rheumatology Clinic: One Clinic’s Experience
Abstract Number: 1838

Estimating Duration of Response in Systemic Lupus Erythematosus (SLE) Trials
Abstract Number: 140

Estimating Prevalence and Cost of Depression Among Japanese RA Patients: A Retrospective Claims Data Base Analysis
Abstract Number: 2707

Estrogen Downregulates the Expression of Serine Arginine Splicing Factor 1 (SRSF1) in Human T Lymphocytes
Abstract Number: 2276

Etanercept (Enbrel®) Treatment Retention in the Sub-Population of Pediatric Patients from a Retrospective Cohort Study Using Canadian Claims-Level Data
Abstract Number: 2797

Etanercept Biosimilar GP2015 Has Equivalent Efficacy and Safety to Etanercept Originator in Patients with Moderate to Severe Rheumatoid Arthritis: The Phase 3 Equira Study
Abstract Number: 2298

Etanercept, Adalimumab and Methotexate Utilization By Juvenile Idopathic Arthritis Patients and the Occurrence of Uveitis
Abstract Number: 733

Ethnic Variation in Systemic Sclerosis Morbidity and Mortality
Abstract Number: 783

European League Against Rheumatisms Recommendations for the Use of Imaging in Large Vessel Vasculitis in Clinical Practice
Abstract Number: 1873

Evaluating Pain Related Disability in Fibromyalgia: A Comparison of the Fibromyalgia Impact Questionnaire and the Polysymptomatic Distress Scale
Abstract Number: 193

Evaluation of a Diversionary Back Pain Service
Abstract Number: 2856

Evaluation of a Dosing Regimen for Tocilizumab in Patients Younger Than Two Years of Age with Systemic Juvenile Idiopathic Arthritis
Abstract Number: 1861

Evaluation of a Longstanding Telephone Peer Counseling Service on People with Systemic Lupus Erythematosus and Their Loved Ones

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].